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Abstract. Curcumin has been widely reported as an anti-inflammatory agent 
isolated from the plant Curcuma longa L. (turmeric). This anti-inflammatory 
activity was associated with the ability of this compound to inhibit the activity of 
both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in arachidonic 
acid metabolism. Dual COX-1 and COX-2 inhibitors are preferred to be 
employed in the therapy of chronic inflammatory diseases compared to selective 
inhibitors, since it was reported that the use of selective inhibitors led to severe 
adverse side effect. In the present study, in vitro and in silico assays on curcumin 
and its analogues as dual inhibitors for both COX-1 and COX-2 were performed. 
The results provide theoretical contribution in understanding the ligand-protein 
interactions at the molecular level to develop new curcumin analogues which 
possess better anti-inflammatory activity as well as to avoid unsolicited side 
effects. 
Keywords: curcumin; cyclooxygenase-1; cyclooxygenase-2; in silico docking; in vitro 
inhibition assay; dual inhibitor.  
1 Introduction 
Curcumin (Figure 1; compound 1a and 1b), the yellow pigment isolated from 
the plant Curcuma longa L. (turmeric), has been reported to have anti-
inflammatory activity, as well as antiviral, antioxidant and anti-infectious 
activities [1,2]. Moreover, in several studies, curcumin caused suppression, 
retardation, or inversion of carcinogenesis [3-6]. The ability of curcumin to 
inhibit prostaglandins (PGs) biosynthesis in the arachidonic acid cascade has 
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been suggested as an important factor for its anti-inflammatory activity and its 
anticarcinogenic action [2-7]. Enzyme cyclooxygenases (COXs), which consist 
of at least two isoforms, i.e., cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2), catalyze the conversion of arachidonic acid to PGH2 in the first two 
steps [3,7,8]. The first isoform, COX-1, has been suggested as a constitutively 
expressed enzyme, which is responsible for maintaining normal physiological 
function [3,8]. On the other hand, the second isoform, COX-2 is inducible and 
the expression is stimulated in the inflammation process [7-9]. At the beginning 
of the discovery of COX-2, therefore, the selectivity towards COX-2 was 
considered as beneficial [10]. However, the withdrawal of Rofecoxib, a 
selective COX-2 inhibitor, due to its increased risk of cardiovascular events, 
raises an issue that the development of the dual inhibitor of the COX-1 and 
COX-2 is of considerable interest [8]. Even more, the COX-1 and COX-2 dual 
inhibitors are suggested to be more appropriate for treating chronic 
inflammation [11].  
 
Figure 1 Structures of curcumin (1) in the keto (1a) and the enol (1b) forms, 
2,5-bis(4-hydroxy-3-methoxybenzilidene)-cyclopentanone (2), 1,5-bis(4-
hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one (3), and flurbiprofen (4). 
Curcumin inhibits the PGs biosynthesis by inhibiting the activity of 
cyclooxygenases (COXs), both cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2) [2-7]. The anti-inflammatory activity of curcumin 
was related to its ability in inhibiting COX-2 as well as lipoxygenase (LOX) [7, 
12]. However, a recent study by Hong et al. [4] suggested that curcumin is more 
selective to ovine COX-1 compared to ovine COX-2. This result led Handler et 
al. [3] to synthesize some curcumin analogues as selective COX-1 inhibitors. 
On the other hand, those results also indicated that curcumin binds to COX-2 as 
well as to COX-1 and results in a significant inhibition [3,4]. Moreover, Padhye 
et al. [13] has reported recently that fluorocurcumin is a COX-2 inhibitor. 
Curcumin, therefore, can serve as a lead compound to develop new inhibitors 
for both COX-1 and COX-2. 
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In silico study in drug design and discovery has flourished together with the 
advance of computer technology [14,15]. The method is promising to increase 
the efficiency and effectiveness of the drug and design processes [14]. A 
number of in silico studies on curcumin have also been reported recently [3,13, 
16,17]. Handler et al. [3] constructed models by using docking method to 
explain the activity of curcumin and its analogue as selective COX-1 inhibitors. 
Other models have been constructed by Padhye et al. [13] to explain the activity 
of curcumin and its fluoro analogues as selective COX-2 inhibitors. Besides 
docking method, another in silico approach named quantitative structure-
activity relationship (QSAR) has been employed as well [16,17]. Appiah-Opong 
et al. [16] generated QSAR models of some curcumin analogues as inhibitors of 
human cytochrome P450 (CYP450) and glutathione S-transferases (GSTs). 
Moreover, Fujisawa et al. [17] performed a QSAR study on a series of 2-
methoxyphenols as COX-2 inhibitors with curcumin as one of the studied 
compound. These studies suggest that in silico study on curcumin and its 
analogues can perform as a complimentary method in the discovery of new 
drugs. 
This article describes in vitro and in silico studies of some analogues of 
curcumin (Figure 1), i.e., 2,5-bis(4-hydroxy-3-methoxybenzilidene)-
cyclopentanone (compound 2), and 1,5-bis(4-hydroxy-3-methoxyphenyl)penta-
1,4-dien-3-one (compound 3) as well as the parent curcumin molecule, both in 
keto tautomer (compound 1a) and enol tautomer (compound 1b) as dual 
inhibitors for COX-1 and COX-2. Compounds 2 and 3 were selected as the 
representatives of the curcumin analogues among those in house analogues 
synthesized by Sardjiman et al. [19] since both have been tested in extensive 
preclinical studies and have the most similar pharmacophore features with 
curcumin [18,19].  
2 Experimental 
2.1 Materials  
Curcumin and its analogues were synthesized by Sardjiman et al. [19]. The 
inhibitory activity of curcumin and its analogues to both COX-1 and COX-2 
were measured using Colorimetric COX (ovine) Inhibitor Screening assay 
purchased from Cayman Chemicals (Cayman Chemical Co., Cat. No. 760111, 
Ann Arbor, MI, USA). 
2.2 The COX-1 and COX-2 (ovine) Inhibitory Assay  
The assay was carried out using a colorimetric COX (ovine) Inhibitor Screening 
Assay Kit (Cayman Chemical Co., Cat. No. 760111) as previously described in 
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Yang, et al. [20]. The final concentrations of both COX-1 and COX-2 in the 
assay are 1.45 % 
v
/v (14.5 mL/L).  
2.3 Molecular Modeling: Hardware and Software  
The docking protocols were performed using Molecular Operating Environment 
(MOE), version 2008 [10], developed by Chemical Computing Group, Inc. 
(Montreal, Canada). Interaction fingerprints (IFP) application developed by 
Marcou and Rognan [21] were performed as the post docking processing. The 
OpenEye’s OEChem1.3 library was used in the IFP computation [21,22]. As 
long as no further explanation is stated, the default setting was used. All 
simulations were performed on a Linux (Ubuntu 8.04 LTS Hardy Heron) 
machine with Intel Core 2 Duo (@ 2.5 GHz) as the processors and 3.00 GB of 
RAM.  
2.4 Preparation of Ligand Structures  
Curcumin (both in keto (1a) and enol form (1b)), its analogues (compound 2-4) 
as well as flurbiprofen (compound 4) as the reference molecule in the docking 
simulations were built in the 2D model in an MOE database viewer. 
Conformational search was then performed on the database using the 
Conformational Import module. The results were then washed and minimized. 
2.5 Docking Simulations  
The 3D coordinates of COX-1 and COX-2 were obtained from the protein data 
bank (http://www.pdb.org/; PDB code: 1eqh and 3pgh, respectively) [23, 24]. 
Both proteins contain the reference molecule flurbiprofen (compound 4), a dual 
inhibitor for COX-1 and COX-2 [23]. The binding sites of both proteins were 
defined by employing the Pocket Selection module in MOE and using the 
binding sites of flurbiprofen in the crystal structures as the references. 
Sequences alignments of these binding sites were performed using ClustalW2 
[25]. Hydrogens were added using the Protonate 3D module in MOE, and only 
ligand and protein in chain A were used from the crystal structures. The proteins 
were subsequently aligned using the Align module in MOE. For each protein, 
Docking Simulation module in MOE was performed using the database 
containing prepared ligands as the input file. The results of the docking 
simulations were subsequently subjected for post docking processing by 
employing IFP guided visual inspection. The protein-ligand interactions 
fingerprint of flurbiprofen in the crystal structures were used as the references 
[23,24]. 
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3 Result and Discussion 
3.1 The COX-1 and COX-2 (ovine) Inhibitory Assay 
In the present study, the inhibitory activity of curcumin (1) and its analogues (2 
and 3) to COX-1 and COX-2 were tested in vitro and in silico. We found that 
the compounds are potent inhibitors for both proteins since they could inhibit 
the activity of the proteins more than 50% in the concentration of 15 M. Some 
selectivity trends were observed; however the statistical analysis showed that 
the differences were not significant. At the beginning of the discovery of COX-
2, which was believed to be more responsible in the inflammatory process 
compared to COX-1, curcumin was believed to be a more selective COX-2 
inhibitor than COX-1 inhibitor [2]. Some previous studies also reported that 
curcumin is highly related to the COX-2 expression and also binds directly to 
COX-2 [7]. However, a recent study by Hong et al. [4] suggested that curcumin 
is more selective to COX-1, which subsequently was supported by Handler et 
al. [3] by synthesizing some curcumin analogues as selective COX-1 inhibitors. 
These previous results underlined that curcumin is inhibitor for both COX-1 and 
COX-2, which was supported by our finding in this study. Moreover, we 
indicated here that compounds 1-3 can be potent dual inhibitors for both COX-1 
and COX-2. Dual COX-1 and COX-2 inhibitors are preferred to be employed in 
the therapy of chronic inflammatory diseases compared to selective inhibitors 
[11], since it was reported that the use of selective inhibitors led to severe 
adverse side effect [8, 9, 11].   
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Figure 2 The inhibitory activity of curcumin and its analogues (15 M) to 
COX-1 and COX-2. The final concentrations of both COX-1 and COX-2 in the 
assay are 1.45 % v/v (14.5 mL/L). Data shown are mean ± SEM of three 
independent experiments. 
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Figure 2 shows the inhibitory activity of compounds 1, 2 and 3 to both COX-1 
and COX-2. The activities range from 68.4-77.8% for COX-1 and 59.3-81.9% 
for COX-2. Compound 2 shows the highest inhibitory activity for both proteins. 
Compound 2 and 3 are more selective towards COX-2, while compound 1 is 
more selective towards COX-1. Statistical analysis using Student’s t-test, 
however, shows that the differences between the inhibitory activities to COX-1 
and to COX-2 are not significant at 95% level of confidence intervals for each 
compound. Moreover, the ANOVA tests show that the differences between the 
inhibitory activities of compounds 1, 2, and 3 are also not significant at 95% 
level of confidence intervals for both COX-1 and COX-2. 
3.2 Docking Studies  
The sequences alignments of binding sites using ClustalW2 (Figure 3) have a 
score of 80. When only residues that perform direct interaction with the 
reference compound (flurbiprofen; compound 4) as indicated in IFP analysis 
were taken into account in the sequence alignments, the score is 94 and 16 out 
of 17 residues are identical. The residues with residue number 523 (ILE in 
COX-1 and VAL in COX-2) are found to be the only ones that differentiates the 
binding site of both enzymes, but still observed as “conserved” in ClustalW2. 
The cross IFP calculation between the crystal structures gives the Tanimoto 
metric Interaction Fingerprint (Tc-IFP) of 1.00 for both enzymes. Table 1 
presents Tc-IFP of the selected pose for each compound. The Tc-IFPs of the 
reference compound docking poses are more than 0.6, i.e. 1.00 and 0.95 in the 
COX-1 and COX-2, respectively. Figure 4 shows the overlay of the crystal 
structure conformation and the docking pose of compound 4 in the binding site 
of COX-1 (Figure 4A) and COX-2 (Figure 4B). Curcumin (compound 1) in the 
keto form (1a) possesses a slightly better Tc-IFP value than it is in the enol 
form (1b) in both COX-1 and COX-2. Figures 5, 6 and 7 present the docking 
poses of curcumin in the keto form (1a), compound 2 and compound 3, 
respectively.  Compounds 1, 2 and 3 are located in the binding site of 
compound 4 of COX-1 and COX-2. All compounds maintain the interaction 
with ARG-120 for both proteins (Figure 4-7). Compound 1 maintains all 
hydrogen bonds possessed by compound 4 in both COX-1 and COX-2 (Figure 
5), i.e. to ARG-120 and TYR-355. Compound 1 in COX-1 has one additional 
hydrogen bond interaction to TYR-385 more than in COX-2 (Figure 5A). 
Compounds 2 and 3 maintain the hydrogen bond interaction to ARG-120 but 
lose the interaction to TYR-355. The - interactions of compounds 1-3 remain 
similar to compound 4. 
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Figure 3 Sequences alignment of the COX-1 (color of carbon atoms are green) 
and COX-2 (color of carbon atoms are cyan) binding sites. The sequences 
alignment was performed using ClustalW2, while the figure was generated by 
employing PyMol v0.99. The alignment shows that the interactions of compound 
4 to COX-1 and COX-2 are identical. Compound 4 from both proteins are 
presented as sticks while the residues in the proteins are presented as lines, 
except that the residue that differentiates both proteins (ILE-523 in COX-1 and 
VAL-523 in COX-2) were presented as sticks.  
Table 1 The Tanimoto metric Interaction Fingerprint (Tc-IFP) of the selected 
pose of curcumin (both in keto and enol forms), its analogues and flurbiprofen. 
Compound 
Tc-IFP 
COX-1 COX-2 
1a 0.83 0.81 
1b 0.78 0.80 
2 0.69 0.72 
3 0.78 0.70 
4 1.00 0.95 
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Figure 4 The overlay of the crystal structure conformations (color of carbon 
atoms are magenta) and the docking poses (color of carbon atoms are yellow) of 
compound 4 in the binding sites of COX-1 (4A) and COX-2 (4B). For the sake 
of clarity only residues that have electrostatic interactions (- interaction and 
hydrogen bonds) with compound 4 and the residue that differs from the protein 
were shown in this figure. Non polar hydrogens are also not shown. Backbone 
and carbon atoms of the proteins are colored as grey, polar hydrogens are 
colored as cyan, oxygen atoms are colored as red and fluoro atoms are colored as 
green. The same depiction settings are applied in Figures 5, 6, and 7. PyMol 
v0.99 was employed to produce these figures. 
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Figure 5 The docking poses (color of carbon atoms are yellow) of compound 
1a in the binding sites of COX-1 (5A) and COX-2 (5B). 
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Figure 6 The docking poses (color of carbon atoms are yellow) of compound 2 
in the binding sites of COX-1 (6A) and COX-2 (6B).  
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Figure 7 The docking poses (color of carbon atoms are yellow) of compound 3 
in the binding sites of COX-1 (7A) and COX-2 (7B). 
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In order to support the suggestion that curcumin and its analogues are dual 
COX-1 and COX-2 inhibitors and to understand the ligand-protein interactions 
in the molecular level, in silico studies were performed. Crystal structures of 
COX-1 and COX-2 that contain flurbiprofen (4), a non selective COX-1/COX-2 
inhibitor, were used as the models [23, 24]. The validations of the protocols 
were performed by re-docking the native substrate, i.e. flurbiprofen (4) [21, 26]. 
We found that the docking protocols can reproduce a similar interaction 
compared to the crystal structure conformations (Tc-IFP  0.6) [21, 26]. The in 
silico screening of compounds 1-3, therefore, can be performed further using 
the docking protocols. Compounds 1-3 are fits in the “non-selective” binding 
sites of COX-1 and COX-2. Compound 1 form hydrogen bonds to residues 
ARG-120, TYR-355 and TYR-385 in COX-1 but only to residues ARG-120 
and TYR-355 in COX-2 (Figure 4). This explains the lower inhibitory activity 
of compound 1 in COX-2 compared to the inhibitory activity in COX-1. 
Compound 2 binds in similar manner both in COX-1 and COX-2. It binds to 
ARG-120. The inhibitory activities of compound 2 in COX-1 and COX-2 are 
similar. The similar inhibitory activity to both COX-1 and COX-2 is also 
observed in compound 3, which shows similar binding interactions an COX-1 
and COX-2. In general, compound 2 posses better inhibitory activity compare to 
compounds 1 and 3. However, the number of hydrogen bonds formed by 
compound 2 is similar to compound 3 and less than compound 1. Compared to 
compounds 1 and 3, compound 2 is more rigid and has less degree of freedom. 
Thus, compound 2 has less entropy compared to compound 1 and 3. This 
indicates that the differences of the COX-1 and COX-2 inhibitory activities of 
compounds 1-3 are determined by the entropy of the system than the enthalpy. 
These in silico screening results support the in vitro data.   
4 Conclusions 
The present results demonstrate that compounds 1-3 bind in the similar manner 
with compound 4 in the binding sites of COX-1 and COX-2 which support the 
in vitro data. Hence, compounds 1-3 could be developed as potent dual COX-1 
and COX-2 inhibitors. Moreover, the understanding of the interactions of 
compounds 1-3 to COX-1 and COX-2 in the molecular level can be further 
studied in silico. The docking protocols developed in this study can serve also 
as protocols for further virtual screening of dual COX-1/COX-2 inhibitors.   
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